论文部分内容阅读
目的探究瑞格列奈联合吡格列酮治疗2型糖尿病的临床疗效。方法选取2013年6月—2014年5月千岛湖镇社区卫生服务中心收治的102例2型糖尿病患者,随机分为观察组(52例)和对照组(50例)。对照组患者采用瑞格列奈治疗,观察组采用瑞格列奈联合吡格列酮治疗。比较两组患者治疗前后空腹血糖(FPG)、餐后2h血糖(2h PG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平及不良反应情况。结果两组患者治疗前FPG、2h PG、FINS、Hb A1c、TG、LDL-C比较,差异无统计学意义(P>0.05);两组患者治疗后FPG、2h PG、FINS、Hb A1c、TG、LDL-C比较,差异有统计学意义(P<0.05)。两组患者均未发生低血糖以及严重的脏器损害等。结论瑞格列奈联合吡格列酮治疗2型糖尿病的疗效显著,且不良反应少。
Objective To investigate the clinical efficacy of repaglinide combined with pioglitazone in the treatment of type 2 diabetes mellitus. Methods A total of 102 patients with type 2 diabetes admitted to Qiandaohu Community Health Service Center from June 2013 to May 2014 were randomly divided into observation group (52 cases) and control group (50 cases). The patients in the control group were treated with repaglinide and the patients in the observation group were treated with repaglinide and pioglitazone. Fasting blood glucose (FPG), postprandial 2h glucose, fasting insulin (FINS), HbA1c, triglyceride (TG) and low density lipoprotein cholesterol (LDL- Level and adverse reactions. Results There were no significant differences in FPG, 2h PG, FINS, Hb A1c, TG and LDL-C between the two groups before treatment (P> 0.05). FPG, 2h PG, FINS, Hb A1c, TG , LDL-C, the difference was statistically significant (P <0.05). No hypoglycemia and serious organ damage occurred in both groups. Conclusion Repaglinide and pioglitazone are effective in treating type 2 diabetes with less adverse reactions.